Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 10/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 9/20 | 0.46 |
| ▸ | PDE4A | P27815 | 8/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 8/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | SLC16A3 | O15427 | 3/20 | 0.39 |
| ▸ | SLC16A1 | P53985 | 2/20 | 0.39 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3608923 | 0.90 | PDE4B (0.46) | PDE4BPDE4DPDE4APDE4CFYN | |
| SCHEMBL4188459 | 0.89 | PDE4B (0.46) | PDE4BPDE4DPDE4APDE4CFYN | |
| SCHEMBL3603031 | 0.89 | PDE4B (0.45) | PDE4BPDE4DPDE4APDE4CFYN | |
| SCHEMBL3604755 | 0.87 | PDE4B (0.46) | PDE4BPDE4DPDE4APDE4CFYN | |
| SCHEMBL3602579 | 0.86 | PDE4B (0.48) | PDE4BPDE4DPDE4APDE4CALDH1A1 | |
| SCHEMBL3595763 | 0.85 | PDE4B (0.47) | PDE4BPDE4DPDE4APDE4CALDH1A1 | |
| SCHEMBL3611624 | 0.85 | PDE4B (0.44) | PDE4BPDE4DPDE4APDE4CFYN | |
| SCHEMBL3611676 | 0.84 | PDE4D (0.45) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL3597283 | 0.84 | PDE4B (0.44) | PDE4BPDE4DPDE4APDE4CFYN | |
| SCHEMBL3611362 | 0.82 | FAAH (0.52) | PDE4BPDE4DPDE4APDE4CALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7495017-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-02-24 | — | — | US | claimed |
| US-20070203197-A1 | Phosphodiesterase 4 inhibitors | HOPPER ALLEN | 2007-08-30 | — | — | US | claimed |
| EP-1631568-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2006-03-08 | — | — | EP | claimed |
| US-20040229918-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2004-11-18 | — | — | US | claimed |
| WO-2004094411-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-11-04 | — | — | WO | claimed |
| US-20090221661-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN | 2009-09-03 | — | — | US | disclosed |
| US-7495017-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-02-24 | — | — | US | disclosed |
| US-20070203197-A1 | Phosphodiesterase 4 inhibitors | HOPPER ALLEN | 2007-08-30 | — | — | US | disclosed |
| US-7226930-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICAL CORPORATION (US) | 2007-06-05 | — | — | US | disclosed |
| EP-1631568-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2006-03-08 | — | — | EP | disclosed |
| US-20040229918-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2004-11-18 | — | — | US | disclosed |
| WO-2004094411-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203197-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | PDE4B 2/4885PDE4D 6/4885PDE4A 1/4885 |
| US-20090221661-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE4B, PDE12 | PDE4B 2/4885PDE4D 6/4885PDE4A 1/4885 |
| US-20040229918-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | PDE4B 2/4885PDE4D 6/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.